Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

T. de la Motte Rouge · SciRah

Researcher profile · Semantic Scholar

T. de la Motte Rouge

Share profile

T. de la Motte Rouge — researcher profile on SciRah

h-index: 25
Works: 206
Citations: 2,577

Most-cited papers

PFMG2025–integrating genomic medicine into the national healthcare system in France
Caroline Abadie, Aldja Abderrahmane, Ouarda Abdous, Carine Abel +496 more
2025The Lancet Regional Health - Europe61 citations Open access
Semantic Scholar
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study.
N. Colombo, E. Zsiros, G. Parma, Eliana Rulli +25 more
2026The Lancet49 citations
Semantic Scholar
PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients.
Thibault Gauduchon, M. Kfoury, D. Lorusso, A. Floquet +16 more
2023Gynecologic Oncology36 citations Open access
Semantic Scholar
LBA3 Pembrolizumab vs placebo plus weekly paclitaxel ± bevacizumab in platinum-resistant recurrent ovarian cancer: Results from the randomized double-blind phase III ENGOT-ov65/KEYNOTE-B96 study
N. Colombo, E. Zsiros, A. Sebastianelli, M. Bidziński +16 more
2025Annals of Oncology35 citations
Semantic Scholar
Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort.
T. Grinda, A. Antoine, W. Jacot, P. Cottu +21 more
2023European Journal of Cancer34 citations Open access
Semantic Scholar
Real-Time Detection of ESR1 Mutation in Blood by Droplet Digital PCR in the PADA-1 Trial: Feasibility and Cross-Validation with NGS.
C. Callens, F. Bidard, Anais Curto-Taribo, O. Trabelsi-Grati +18 more
2022Analytical Chemistry28 citations
Semantic Scholar
Impact of lobular versus ductal histology on overall survival in metastatic breast cancer: a French retrospective multicentre cohort study.
F. Dalenc, A. Lusque, T. de la Motte Rouge, B. Pistilli +17 more
2022European Journal of Cancer24 citations
Semantic Scholar
Abstract GS3-05: Fulvestrant-palbociclib vs continuing aromatase inhibitor-palbociclib upon detection of circulating ESR1 mutation in HR+ HER2- metastatic breast cancer patients: Results of PADA-1, a UCBG-GINECO randomized phase 3 trial
F. Bidard, A. Hardy-Bessard, T. Bachelot, J. Pierga +24 more
2022Cancer Research21 citations
Semantic Scholar
Kinetics and determinants of ESR1 mutation detection in metastatic breast cancer.
L. Cabel, F. Berger, T. Bachelot, B. Pistilli +12 more
2025Annals of Oncology19 citations
Semantic Scholar
Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program
D. B. Roufai, A. Gonçalves, T. de la Motte Rouge, S. Akla +20 more
2023Oncogene19 citations Open access
Semantic Scholar
Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER+/HER2- breast cancer.
A. Mamann, Y. Pradat, F. Bidard, S. Delaloge +21 more
2025Annals of Oncology15 citations Open access
Semantic Scholar
MOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumors
C. Vicier, N. Isambert, C. Cropet, M. Hamimed +5 more
2022ESMO Open15 citations Open access
Semantic Scholar
Management of trophoblastic tumors : review of evidence, current practice, and future directions
A. Deleuze, C. Massard, Fanny Le Du, B. You +3 more
2023Expert Review of Anticancer Therapy13 citations
Semantic Scholar
Dynamics and type of ESR1 mutations under aromatase inhibitor or fulvestrant combined with palbociclib after randomization in the PADA-1 trial.
L. Cabel, S. Delaloge, A. Hardy-Bessard, F. André +16 more
2023Journal of Clinical Oncology12 citations
Semantic Scholar
Impact of surgery and chemotherapy in ovarian sex cord-stromal tumors from the multicentric Salomé study including 469 patients. A TMRG and GINECO group study.
B. Hanvic, F. Lécuru, H. Vanacker, P. Pautier +22 more
2023Gynecologic Oncology11 citations Open access
Semantic Scholar
Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy.
C. Vulsteke, Setsuko K. Chambers, Maria Jesús Rubio Pérez, John K. Chan +16 more
2024European Journal of Cancer10 citations Open access
Semantic Scholar
Development of sensitive and robust multiplex digital PCR assays for the detection of ESR1 mutations in the plasma of metastatic breast cancer patients.
J. Corné, V. Quillien, C. Callens, Pascal Portois +12 more
2023Clinica chimica acta; international journal of clinical chemistry10 citations Open access
Semantic Scholar
Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation
J. Frenel, A. Lusque, S. Delaloge, J. Ferrero +16 more
2023British Journal of Cancer9 citations Open access
Semantic Scholar
Efficacy of taxanes rechallenge in first-line treatment of early metastatic relapse of patients with HER2-negative breast cancer previously treated with a (neo)adjuvant taxanes regimen: A multicentre retrospective observational study
A. Vasseur, M. Carton, S. Guiu, P. Augereau +18 more
2022Breast9 citations Open access
Semantic Scholar
Academic Randomized Phase II Trial Assessing The Inhibitor Of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab In Combination With Chemoradiation In Locally Advanced Cervical Cancer (ATEZOLACC Trial)
C. Chargari, Patricia Pautier, D. Chaltiel, Adeline Petit +27 more
2025International Journal of Gynecological Cancer8 citations
Semantic Scholar
Plasma‐based analysis of ERBB2 mutational status by multiplex digital PCR in a large series of patients with metastatic breast cancer
J. Corné, V. Quillien, F. Godey, Mathilde Cherel +10 more
2024Molecular Oncology8 citations Open access
Semantic Scholar
Real-world dostarlimab use in advanced/recurrent endometrial cancer in France.
M. Rodrigues, Lauriane Eberst, P. Follana, Ludiane Gauthier +11 more
2023Bulletin du Cancer8 citations Open access
Semantic Scholar
BRCA1 and RAD51 methylation impact on outcome in patients with advanced ovarian cancer: A PAOLA-1 ancillary study.
H. Blons, J. Abdelli, V. Taly, C. Mulot +16 more
2023Journal of Clinical Oncology8 citations
Semantic Scholar
ENGOT-ov65/KEYNOTE-B96: Phase 3, randomized, double-blind study of pembrolizumab versus placebo plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer.
N. Colombo, R. Coleman, Xiao-Hua Wu, F. Kose +16 more
2022Journal of Clinical Oncology8 citations
Semantic Scholar
Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial
G. Valabrega, B. Pothuri, A. Oaknin, W. Graybill +16 more
2024Gynecologic Oncology7 citations Open access
Semantic Scholar
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial
A. Ginzac, I. Molnar, X. Durando, T. de la Motte Rouge +17 more
2024Breast Cancer Research and Treatment6 citations Open access
Semantic Scholar
Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1/2 mutations
W. Jacot, A. Lusque, C. Vicier, A. Mailliez +13 more
2022British Journal of Cancer6 citations Open access
Semantic Scholar
Durvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II study
J. Frenel, L. Mathiot, C. Cropet, E. Borcoman +11 more
2025Journal for ImmunoTherapy of Cancer5 citations Open access
Semantic Scholar
712MO Final overall survival (OS) from the phase III ATALANTE/ENGOT-ov29 trial evaluating atezolizumab (Atz) versus placebo with standard chemotherapy (Cx) plus bevacizumab (bev) in ovarian cancer (OC) patients (pts) with platinum-sensitive relapse (PSR)
J. Kurtz, E. Pujade-Lauraine, A. Oaknin, L. Belin +16 more
2024Annals of Oncology5 citations Open access
Semantic Scholar
Abstract CT084: A phase 1 study of LY4101174 (ETx-22), an antibody-drug conjugate targeting nectin-4, in patients with advanced or metastatic urothelial cancer and other solid tumors (trial in progress)
J. Rosenberg, R. Sabatier, Armelle Viceneux, T. de la Motte Rouge +22 more
2024Cancer Research5 citations
Semantic Scholar
Tumor-intrinsic chemosensitivity assessed by KELIM and prognosis by BRCA status in patients with advanced ovarian carcinomas
Ondine Becker, A. Durand, M. Chevrier, Laetitia Collet +22 more
2024International Journal of Gynecological Cancer5 citations Open access
Semantic Scholar
Phase Ib INEOV neoadjuvant trial of durvalumab +/- tremelimumab with platinum chemotherapy for patients (pts) with unresectable ovarian cancer (OC): Survival outcomes and immune correlates.
A. Leary, Laure Chardin, Alain Lortholary, B. Asselain +12 more
2024Journal of Clinical Oncology5 citations Open access
Semantic Scholar
Consensus on drivers of maintenance treatment choice and patterns of care in advanced ovarian cancer
Alejandro Pérez-Fidalgo, B. Schmalfeldt, A. George, Charlie Gourley +16 more
2024International Journal of Gynecological Cancer5 citations Open access
Semantic Scholar
Pembrolizumab vs placebo plus weekly paclitaxel ± bevacizumab in platinum-resistant recurrent ovarian cancer: final analysis results from the randomized double-blind phase 3 ENGOT-ov65/KEYNOTE-B96 study
N. Colombo, E. Zsiros, A. Sebastianelli, R. Mądry +16 more
2026International Journal of Gynecological Cancer4 citations
Semantic Scholar
PEMBROLIZUMAB VS PLACEBO PLUS PACLITAXEL ± BEVACIZUMAB FOR PLATINUM-RESISTANT RECURRENT OVARIAN CANCER: RESULTS FROM THE PHASE 3 ENGOT-OV65/KEYNOTE-B96 STUDY
N. Colombo, E. Zsiros, A. Sebastianelli, M. Bidziński +16 more
2025International Journal of Gynecological Cancer4 citations
Semantic Scholar
Predictive value of BRCA1/RAD51C methylation in HGSOC - An ancillary study of the PAOLA-1/ENGOT-ov25 phase 3 trial.
H. Blons, J. Abdelli, S. Landman, V. Taly +17 more
2025European Journal of Cancer4 citations
Semantic Scholar
Real-World Data on Olaparib in Relapsed BRCA-mutated Ovarian Cancer: A Multicenter GINECO RETROLA Cohort Study
H. Bourien, L. Lefevre, M. Mouret-Reynier, B. Asselain +17 more
2023Anticancer Research4 citations Open access
Semantic Scholar
707 A Phase 1, open-label, dose finding study of NI-1801, a bispecific mesothelin x CD47 engaging antibody, in patients with mesothelin expressing solid cancers
E. Romano, J. Medioni, T. de la Motte Rouge, N. Fischer +6 more
2022Regular and Young Investigator Award Abstracts4 citations Open access
Semantic Scholar
EMITT-1: Clinical and pharmacodynamic activity with the oral ERAP1 inhibitor GRWD5769 and cemiplimab in 6 completed phase 1b expansion cohorts in solid tumors with anti–PD-1 resistance or MSS-CRC.
F. Thistlethwaite, Desamparados Roda, Eduardo Castañón Álvarez, V. Moreno +16 more
2026Journal of Clinical Oncology3 citations
Semantic Scholar
TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer
R. Kabirian, O. Tredan, F. Marmé, Xavier Paoletti +16 more
2024Future Oncology3 citations Open access
Semantic Scholar
Real-world evidence of the management and prognosis of young women (⩽40 years) with de novo metastatic breast cancer
Amélie Mallet, A. Lusque, C. Lévy, B. Pistilli +19 more
2022Therapeutic Advances in Medical Oncology3 citations Open access
Semantic Scholar
Phase Ib INEOV neoadjuvant trial of durvalumab +/- tremelimumab with platinum chemotherapy for patients (pts) with unresectable ovarian cancer (OC): Final complete resection and pathological response rates.
A. Leary, T. de la Motte Rouge, A. Lortholary, B. Asselain +11 more
2022Journal of Clinical Oncology3 citations
Semantic Scholar
Real-World Data on Newly Diagnosed BRCA-Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database
M. Bini, S. Quesada, P. Meeus, M. Rodrigues +21 more
2022Cancers3 citations Open access
Semantic Scholar
Abstract P1-07-01: Real time detection of ESR1 mutation in blood by droplet digital PCR in the PADA-1 trial: Feasibility and cross-validation with NGS
C. Callens, F. Bidard, Anais Curto-Taribo, O. Trabelsi-Grati +17 more
2022Cancer Research3 citations
Semantic Scholar
Efficacy and safety of immune checkpoint inhibitor rechallenge in cervical and endometrial cancer: a multi-center retrospective study (RICE study).
R. Kabirian, Mathilde de Saint Ghislain, O. Le Saux, L. Mathiot +15 more
2026International Journal of Gynecological Cancer2 citations
Semantic Scholar
Role of platinum-free interval (PFI) and maintenance therapies in recurrent ovarian cancer to explain survival. An analysis from the French real-world ESME Ovarian Database.
Claire Chator, M. Chevrier, J. Frenel, Frédéric Guyon +16 more
2025Gynecologic Oncology2 citations
Semantic Scholar
Tremelimumab plus durvalumab combined to metronomic oral vinorelbine: Results from the breast cancer cohort of the phase II MOVIE study
T. de la Motte Rouge, J. Frenel, C. Cropet, E. Borcoman +7 more
2025Breast2 citations Open access
Semantic Scholar
Clinical utility of ctDNA as a tool to detect triple-negative breast cancer relapses: The CUPCAKE trial.
F. Bidard, F. Berger, M. Arnedos, M. Mouret-Reynier +13 more
2024Journal of Clinical Oncology2 citations
Semantic Scholar
Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program
D. B. Roufai, A. Gonçalves, T. de la Motte Rouge, S. Akla +20 more
2023Oncogene2 citations Open access
Semantic Scholar
Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 2022–2023 : Prise en charge du cancer du col de l'utérus avancé
P. Pautier, C. Genestie, L. Gladieff, J. Kurtz +9 more
2023Bulletin du Cancer2 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. Frenel×9
Invite
J. Frenel — researcher profile on SciRah
F. Dalenc×8
Invite
F. Dalenc — researcher profile on SciRah
I. Desmoulins×8
Invite
I. Desmoulins — researcher profile on SciRah
B. Pistilli×8
Invite
B. Pistilli — researcher profile on SciRah

×8

Invite

T. Bachelot — researcher profile on SciRah

Invite

C. Lévy — researcher profile on SciRah

Invite

S. Delaloge — researcher profile on SciRah

A. Gonçalves×6

Invite

A. Gonçalves — researcher profile on SciRah

Invite

L. Uwer — researcher profile on SciRah

Invite

F. Bidard — researcher profile on SciRah

A. Hardy-Bessard×6

Invite

A. Hardy-Bessard — researcher profile on SciRah

M. Mouret-Reynier×6

Invite

M. Mouret-Reynier — researcher profile on SciRah